Obsolete test for prostate cancer screening; preferred test is Prostate Specific Antigen, Total (0070121) in conjunction with digital rectal exam.
Quantitative Chemiluminescent Immunoassay
Within 24 hours
New York DOH Approval Status
Specimen should be obtained before rectal examination, biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PAP levels persisting up to 24-48 hours.
Serum separator tube.
Allow specimen to clot completely at room temperature. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Frozen. Separate specimens must be submitted when multiple tests are ordered.
Specimens refrigerated more than 24 hours or left at room temperature more than 3 hours.
After separation from cells: Ambient: 3 hours; Refrigerated: 24 hours; Frozen: 6 months
The Siemens Immulite 2000 PAP chemiluminescent immunoassay method is used. Results obtained with different assay methods or kits cannot be used interchangeably. PAP may be of some use in predicting disease recurrence or monitoring treatment effects. It has little clinical utility as a screening test for prostate cancer. Prostate specific antigen (PSA) is the preferred test for prostate cancer screening, monitoring, and predicting outcomes. Benign prostatic hyperplasia, prostate massage, and prostatic infarction may result in elevated PAP concentrations. The PAP assay value, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease.
|Component Test Code*||Component Chart Name||LOINC|
|0070120||Prostatic Acid Phosphatase||20420-6|
- Acid Phosphatase
- Acid Phosphatase, Prostatic Isoenzyme,